NASDAQ:LIMN Liminatus Pharma (LIMN) Stock Price, News & Analysis $3.70 -0.14 (-3.65%) Closing price 09/3/2026 04:00 PM EasternExtended Trading$3.84 +0.15 (+3.92%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Liminatus Pharma Stock (NASDAQ:LIMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Liminatus Pharma alerts:Sign Up Key Stats Today's Range$3.61▼$3.9150-Day Range$3.64▼$7.5052-Week Range$3.42▼$154.50Volume22,526 shsAverage Volume629,532 shsMarket Capitalization$4.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA. Read More Liminatus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreLIMN MarketRank™: Liminatus Pharma scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLiminatus Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLiminatus Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Liminatus Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Liminatus Pharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Liminatus Pharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLiminatus Pharma has a P/B Ratio of 16.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1,266.06% of the float of Liminatus Pharma has been sold short.Short Interest Ratio / Days to CoverLiminatus Pharma has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Liminatus Pharma has recently increased by 143.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLiminatus Pharma does not currently pay a dividend.Dividend GrowthLiminatus Pharma does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Liminatus Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Liminatus Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.40% of the stock of Liminatus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsLiminatus Pharma has minimal institutional ownership at this time.Read more about Liminatus Pharma's insider trading history. Receive LIMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liminatus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIMN Stock News HeadlinesLiminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyAugust 24, 2026 | globenewswire.comLiminatus Pharma, Inc. Announces Reverse Stock Split of its Common StockAugust 18, 2026 | globenewswire.comHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.September 4 at 1:00 AM | SmartAsset (Ad)Liminatus Pharma Inc (LIMN)August 14, 2026 | investing.comLiminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price RequirementAugust 13, 2026 | globenewswire.comLIMN Share News TodayJuly 6, 2026 | uk.investing.comLiminatus Pharma Inc.: Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy PipelineJuly 1, 2026 | finanznachrichten.deLiminatus Pharma Inc. - Ordinary Shares - Class AJuly 1, 2026 | money.usnews.comSee More Headlines LIMN Stock Analysis - Frequently Asked Questions How have LIMN shares performed this year? Liminatus Pharma's stock was trading at $30.50 at the beginning of 2026. Since then, LIMN shares have decreased by 87.9% and is now trading at $3.70. How were Liminatus Pharma's earnings last quarter? Liminatus Pharma Inc. (NASDAQ:LIMN) announced its quarterly earnings results on Friday, August, 14th. The company reported ($1.50) earnings per share for the quarter. When did Liminatus Pharma's stock split? Shares of Liminatus Pharma reverse split on Friday, August 21st 2026.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 20th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Liminatus Pharma's major shareholders? Top institutional investors of Liminatus Pharma include Cygnus Capital Advisors LLC (24.58%). How do I buy shares of Liminatus Pharma? Shares of LIMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today9/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LIMN Previous SymbolNASDAQ:LIMN CIK1971387 Webliminatuspharma.com Phone(213) 273-5453FaxN/AEmployeesN/AYear Founded1996Profitability EPS (Trailing Twelve Months)($23.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.21 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-256.58% Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio1.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book16.82Miscellaneous Outstanding Shares1,340,000Free Float1,082,000Market Cap$4.96 million OptionableN/A Beta5.30 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:LIMN) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
